THERESON's vision and history

The aging population, the world-wide increase in the high incidence of vascular and metabolic diseases, and the expansion of a disabling issue, capable of worsening the quality of life: Skin ulcers.

It is estimated that around 3% of the population over 60 years of age suffer from chronic ulcers in the lower limbs, reaching 5% of the population over 80 years of age (1).

It is also estimated that around 3% of the world’s medical costs are related to wound care (2).

This alarming data has prompted THERESON, an Italian biomedical company, to invest (since 2011) in the development and diffusion of TMR® Therapeutic Magnetic Resonance.

THERESON has therefore dedicated itself to clinical and scientific research and has as its aim to demonstrate the effectiveness of the THERESON treatment. THERESON also seeks to explore more profoundly the functioning principle behind the interaction between pulsed magnetic fields of particular shape and frequency and the damaged biological tissue. THERESON is particularly interested in the concomitant presence of chronic systemic diseases, such as, for example, diabetes.

Evidence was collected through in-vitro and in-vivo biology tests and two clinical trials on patients with Diabetic Foot. A biophysical model was then developed to help understand why the pulsed fields of TMR®, at low frequency and low intensity, were effective in improving circulation, healing ulcers, reducing inflammation and the perception of pain.

Starting from Wound Care, a sector transversal to the various medical specializations, THERESON was able to further investigate the possible applications of TMR® Therapeutic Magnetic Resonance outside its first application area, such as the orthopedic sector.

The in-vitro analysis confirmed the TMR® ability to stimulate the production of osteoblasts and osteogenic genes.

These first results, together with the observation of the benefits in terms of orthopedic diseases (e.g. acute and chronic inflammations, trauma and surgical injuries, pain), have encouraged THERESON to open up to the orthopedic sector.

For all scientific activities, therefore, a multidisciplinary team has been created, with highly qualified THERESON staff, able to coordinate and collaborate with the research activity of universities and hospitals.
In particular:

  • University of Padua, Department of Biomedical Sciences, led by Prof. Rizzuto, today Magnificent Rector, and by Prof. Zavan, for cell tests;
  • Cisanello University Hospital of Pisa, Diabetic Foot Section led by Prof. Alberto Piaggesi;
  • Cà Foncello Hospital of Treviso, Dott.ssa Sambataro;
  • Nursing home Dott. Pederzoli of Peschiera del Garda, Dott. Nicoletti;
  • Kiev Institute of Theoretical Physics, Prof.ssa Larissa Brizhik (biophysical model).

The extensive data collected has already been partly published and some data is still waiting for publication.

THERESON also wishes to make its technology available to patients. Towards this end, it has developed DIAPASON®, the first medical device that implements the TMR® method. DIAPASON® is already present in Italy and abroad, thanks to the collaboration with qualified Wound Care partners and of the Orthopedic sector.

Improve the quality of life and restore well-being to people with an effective therapeutic device that is easy for the patient to use at home: This is the vision of THERESON.

Innovation, product quality, attention to the patient: The corporate paradigms.

(1) Agale S.V. Chronic Leg Ulcers: Epidemiology, Aetiopathogenesis, and Management Ulcers 2013

(2) Posnett, J. Gottrup, F., Lunggren, H., et al, The resource impact wounds on health-care providers in Europe. J Wound Care 2009; 18:4, 154-161

Request information

Our technicians, salespeople and doctors are at your disposal for any clarification. We invite you to fill in the form or contact us directly.


Fill in the requested info:

CompanyPrivateMedical facilityInvestor